László Herszényi

Epidemiology of gastrointestinal and liver tumors.

László Herszényi, Zsolt Tulassay · PubMed · 2010 · 387 citations

Medicine, Oncology, Cancer Epidemiology +16

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

Bruce E. Sands, Peter M. Irving, Timothy Hoops et al. · The Lancet · 2022 · 297 citations · Full text

Medicine, Clinical Sciences, Immunology +17

Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohnʼs disease patients

Pál Miheller, Györgyi Műzes, István Hritz et al. · Inflammatory Bowel Diseases · 2009 · 123 citations · Full text

Medicine, Endocrinology, Nutritional Sciences +17

Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer

László Herszényi, Fabio Farinati, Romilda Cardin et al. · BMC Cancer · 2008 · 112 citations · Full text

Medicine, Oncology, Pathology +17

Effect of Proton-Pump Inhibitor Therapy on Serum Chromogranin A Level

István Pregun, László Herszényi, Márk Juhász et al. · Digestion · 2011 · 91 citations

Medicine, Pharmacology, Pharmacotherapy +15